J&J Vision receives FDA clearance for astigmatism management software

Article

Catalys cOS 6.0 allows for more accurate laser alignment

Johnson & Johnson Vision’s new astigmatism management software, Catalys cOS 6.0, received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The software package is used in conjunction with its laser cataract surgery system to enable more accurate laser alignment.

It automatically compensates for cyclorotation, or torsional movement of the eye, according to the company.

The astigmatism software offers new features that streamline workflow by speeding up surgical processes and improving accuracy for surgeons using the Catalys Precision Laser system. According to J&J Vision, it does this by:

  • Minimizing manual transcription errors and data entry verification through direct input of preoperative keratometry and steep axis values data
  • Reducing calculation time by including calculations of arcuate incision parameters using built-in nomogram and automatic input of arcuate incision parameters in the treatment planning screen
  • Reducing the need for intraoperative aberrometry for toric IOL alignment with radial laser marks placed within a mean accuracy of 0.6 degrees.
  • Adding iris registration for automatic cyclorotation compensation

Catalys cOS 6.0 will be available in the fourth quarter of 2020.

Read more: AOA elects '20-'21 officer slate via virtual ballot

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
ODs reflect on their time in Minneapolis, Minnesota, citing continuing education, tech updates, and networking opportunities as valued takeaways from the meeting.
Nora Lee Cothran, OD, FAAO, discussed the importance of optometrists addressing mental health with patients in their chair.
Nora Lee Cothran, OD, FAAO, moderated an Innovation Hub panel that featured 3 companies, giving insights into what's to come in the optometric industry.
Selina McGee, OD, shares what she wants to see in future State of Dry Eye surveys and how this year's results will affect her patient care.
Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.
Shawn Hobbs, OD, previews the annual NOA convention, which takes place in Columbus, Ohio, from July 10 to 12, 2025.
© 2025 MJH Life Sciences

All rights reserved.